ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) signed a nationwide distribution agreement with U-Deliver to supply its recently launched over-the-counter reusable ENFit Syringe line through non-acute channels. The syringes are available OTC via U-Deliver website, Amazon storefront, and wholesale in 2.5, 5, 10 and 60 mL sizes.
The ENFit syringes meet ISO 80369-3 standards and are designed for reuse up to seven days or 20 uses, aimed at improving enteral care access in home and long-term care settings.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FEED gained 119.05%, reflecting a significant positive market reaction. Argus tracked a peak move of +272.4% during that session. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $5M at that time. Trading volume was exceptionally heavy at 134.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Orthopedic, Prosthetic & Surgical Appliances & Supplies sector appeared in the momentum scanner, suggesting this partnership news was stock-specific rather than part of a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Leadership appointment | Positive | +2.4% | Hired VP, Commercial with 35+ years of medical device experience. |
| Jan 14 | Product launch | Positive | -26.7% | Launched OTC reusable ENFit syringes for feeding and medication delivery. |
| Jan 09 | Clinical program | Positive | -7.6% | Initiated program using NanoVibronix vibration tech for NG tube discomfort. |
| Jan 08 | Corporate event | Positive | +11.1% | Nasdaq Opening Bell ceremony highlighting enteral and pain-management focus. |
| Dec 15 | Governance change | Positive | -5.6% | Appointed experienced healthcare executive as Chairman of the Board. |
Recent history shows mixed reactions to largely positive news, with 3 divergence events versus 2 aligned moves.
Over the past several weeks, ENvue Medical reported leadership changes, product launches, and visibility events. On Dec 15, 2025, a new chairman was appointed, and expansion of its 510(k)-cleared system into more than 38 hospitals was highlighted. Early January 2026 brought a Nasdaq bell-ringing, an NG-tube pain program, and the OTC ENFit syringe launch, with price reactions both positive and negative. The Jan 21, 2026 commercial leadership hire underscored U.S. commercialization efforts, providing context for today’s distribution-focused partnership.
Market Pulse Summary
The stock surged +119.0% in the session following this news. A strong positive reaction aligns with the company’s recent push into over-the-counter ENFit syringes and broader commercialization. This partnership adds national non-acute distribution on top of the Jan 14, 2026 launch. However, past news saw mixed price follow-through, with 3 of the last 5 events diverging from seemingly positive catalysts, suggesting that enthusiasm sometimes faded after initial moves.
Key Terms
enfit technical
iso 80369-3 technical
enteral medical
AI-generated analysis. Not financial advice.
Distribution agreement leverages U-Deliver’s digital and wholesale channels to expand access to ENvue’s recently launched ENFit Syringes across non-acute care channels
TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue’s recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels.
“We believe that our partnership with U-Deliver is an important step in scaling ENvue’s over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care market,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We’re focused on providing patients and caregivers with reliable, safe solutions for feeding and medication delivery, and supporting continuity of care beyond the hospital. We’re pleased to work with a partner that understands the needs of home and long-term care.”
“We are excited to partner with ENvue, an organization that shares our mission to make tube feeding easier,” said Brian Johnson, President & Co-Founder of U-Deliver. “Through our digital and wholesale channels, we believe we are positioned to broaden access to ENvue’s ENFit syringes while delivering the quality and affordability our customers expect. This partnership reinforces a shared commitment to patient safety and product accessibility across non-acute care settings.”
ENvue’s ENFit Syringes are currently available through U-Deliver’s website, Amazon storefront, and wholesale channels in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, without the need for a prescription. The ENFit syringes meet ISO 80369-3 global standards and are designed for reuse for up to seven days or 20 uses, supporting safe and consistent enteral delivery in both clinical and home care environments.
About U-Deliver
U-Deliver is a U.S.-based supplier focused on enteral feeding supplies for patients and caregivers in home and long-term care settings. The company serves non-acute care customers through online and distribution channels. For more information, visit www.udelivermedical.com.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Raquel Cona, Vice President
PH: (516) 779-2630
envue@kcsa.com
FAQ
What does ENvue Medical (FEED) announce about distribution with U-Deliver on January 28, 2026?
Are ENvue’s ENFit syringes available without a prescription for FEED investors and patients?
What sizes and reuse guidance does ENvue provide for its ENFit syringes (FEED)?
Do ENvue ENFit syringes (FEED) meet industry standards for enteral devices?
How will U-Deliver’s channels affect ENvue’s market reach for FEED products?
What is the strategic aim of ENvue Medical’s (FEED) partnership with U-Deliver?
